Log in

NYSE:ABBV - AbbVie Stock Price, Forecast & News

$75.13
+1.71 (+2.33 %)
(As of 04/3/2020 01:14 AM ET)
Today's Range
$71.46
Now: $75.13
$75.50
50-Day Range
$64.50
MA: $84.03
$97.79
52-Week Range
$62.55
Now: $75.13
$97.86
Volume8.07 million shs
Average Volume17.17 million shs
Market Capitalization$110.94 billion
P/E Ratio14.23
Dividend Yield6.20%
Beta0.84
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More
AbbVie logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.19 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,476,670,000
Market Cap$110.94 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABBV stock has decreased by 11.5% and is now trading at $75.13. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AbbVie?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AbbVie.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for AbbVie.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings data on Friday, February, 7th. The company reported $2.21 EPS for the quarter, beating the Zacks' consensus estimate of $2.19 by $0.02. The company earned $8.70 billion during the quarter, compared to analyst estimates of $8.68 billion. AbbVie had a net margin of 23.69% and a negative return on equity of 162.54%. AbbVie's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.90 earnings per share. View AbbVie's earnings history.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, February 20th. Investors of record on Wednesday, April 15th will be given a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 annualized dividend and a dividend yield of 6.28%. The ex-dividend date of this dividend is Tuesday, April 14th. View AbbVie's dividend history.

How will AbbVie's stock buyback program work?

AbbVie declared that its board has initiated a share repurchase plan on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its stock is undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY20 earnings guidance on Friday, February, 7th. The company provided EPS guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus estimate of $9.78.

What price target have analysts set for ABBV?

14 equities research analysts have issued 1-year target prices for AbbVie's stock. Their forecasts range from $78.00 to $105.00. On average, they anticipate AbbVie's stock price to reach $91.83 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price. View analysts' price targets for AbbVie.

Has AbbVie been receiving favorable news coverage?

Media stories about ABBV stock have been trending very negative recently, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AbbVie earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional investors include Park National Corp OH (0.01%), Thomasville National Bank (0.01%), Neville Rodie & Shaw Inc. (0.01%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%), Birch Capital Management LLC (0.00%) and Bath Savings Trust Co (0.00%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Cullinan Associates Inc., Fulcrum Equity Management, Birch Capital Management LLC, Thomasville National Bank, and Private Asset Management Inc.. View insider buying and selling activity for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Bath Savings Trust Co, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $75.13.

How big of a company is AbbVie?

AbbVie has a market capitalization of $110.94 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe. View additional information about AbbVie.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com/.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,153 (Vote Outperform)
Underperform Votes:  825 (Vote Underperform)
Total Votes:  1,978
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel